BARDA Procures Regeneron’s Investigational Ebola Treatment
HHS’ Biomedical Advanced Research and Development Authority (BARDA) has issued a multi-year contract to Regeneron for a supply of the company’s investigational Ebola treatment REGN-EB3.
Under the agreement, Regeneron will deliver doses of the is a triple antibody cocktail over the next six years if the FDA approves the drug. The company will receive $10 million for the doses in 2021 and an average of $67 million per year between 2022-2026.
REGN-EB3 is a getting a priority review by the FDA. The agency is expected to issue a decision on the drug by Oct. 25, 2020.